Biological shares rose by the daily limit and closed at 15.94 yuan. The stock rose by the limit at 10:05, opened the limit 16 times, and closed its closing order with a capital of 6.9785 million yuan, accounting for 0.04% of its current market value.

In terms of capital flow data, the net inflow of main funds on the same day was 42.5984 million yuan, the net inflow of hot capital was 16.77 million yuan, and the net outflow of retail funds was 25.3859 million yuan. The flow of funds in the past five days is shown in the following table:

The stock is animal health, bird flu, Inner Mongolia concept hot stocks, the same day animal health concept rose 2.48%, bird flu concept rose 2.16%, Inner Mongolia concept rose 1.43%.

The investment logic of the stock is as follows:

1. The comprehensive research and production capacity of avian influenza animal vaccine are in the leading level in China.

2. Private enterprises with no real controllers; main business is bio-pharmaceuticals; foot-and-mouth disease vaccine is the company's leading product.

3. The overlord of foot-and-mouth disease, known as China Shuoteng, the leading vaccine in the high-end market, has formulated the quality and testing standards of foot-and-mouth disease vaccine, and has the only "national engineering laboratory of veterinary vaccine" in China; products include foot-and-mouth disease vaccine, brucellosis vaccine, swine fever vaccine, pig ring vaccine, pig blue ear vaccine, swine pseudorabies attenuated vaccine, duck Tambusu virus inactivated vaccine, etc. A joint venture company was set up in October 1919 to open up the pet vaccine market, with an annual biopharmaceutical revenue of 1.077 billion yuan, accounting for more than 95% of the total.

From the perspective of financial situation, the third quarterly report of Biological shares 2021 showed that the company's main income was 1.338 billion yuan, up 20.82% from the same period last year; the net profit from its parent was 419 million yuan, up 41.55% from the same period last year; and deducting 388 million yuan from non-net profit, up 33.45% over the same period last year. Among them, the company's main income in the third quarter of 2021 was 498 million yuan, up 3.02% from the same period last year. The net profit of returning to the mother in a single quarter was 161 million yuan, up 41.83% from the same period last year; the non-net profit in the single quarter was 136 million yuan, up 23.43% from the same period last year; the debt ratio was 14.91%, the investment income was 2.7554 million yuan, the financial expenses were-28.48 million yuan, and the gross profit margin was 62.11%.

The Securities Star valuation analysis tool shows that the biological shares (600201) good company has a rating of 3.5star, a good price rating of 3.5star, and a comprehensive valuation rating of 3.5star. A total of 12 agencies rated the stock in the last 90 days, including 10 buy ratings and 2 overweight ratings; the average institutional target price in the past 90 days was 23.63; in the past three months, the net financing outflow was 35.7679 million, and the financing balance decreased; the net inflow of securities was 2.7274 million, and the balance of securities lending increased.

This article is compiled by the Securities Star data Center according to the public data and does not constitute investment opinions or suggestions. If there are any questions in the article, please contact us.